Background Building on the declining trend of malaria in Ethiopia, the Federal Ministry of
Health aims to eliminate malaria by 2030. As Plasmodium falciparum and Plasmodium vivax …

Background: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an X-linked
hereditary disorder and a global public health concern that is most prevalent in malaria …

Approximately 18 million people live in malaria-endemic areas with 218,450 reported
confirmed cases and 161 reported deaths in Indonesia. Currently, primaquine (PQ), the 8 …

Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) is a metabolic enzyme
involved in the pentose phosphate pathway, its especially important in red blood cell …

A community-based survey was conducted to assess the prevalence of G6PD deficiency
and malaria in two villages (St. Martins, Dagua) of Wewak district, East Sepik Province …

Haiti is one of two remaining malaria-endemic countries in the Caribbean. To decrease
malaria transmission in Haiti, primaquine was recently added to the malaria treatment public …

Background Primaquine, the only available drug effective against Plasmodium falciparum
sexual stages, induces also a dose-dependent haemolysis, especially in glucose-6 …

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is one of the most common
inherited enzymopathies in endemic areas of malaria including Southeast Asia. The …

Abstract Background Glucose-6-phosphate dehydrogenase (G6PD) is cytosolic enzyme,
which has a vital role for the integrity and functioning of red blood cells. Lower activity of this …

Background Control of malaria increasingly involves administration of 8-aminoquinolines,
with accompanying risk of haemolysis in individuals with glucose-6-phosphate …